Sunday, March 14, 8:00 AM - 9:30 AM
This is one of those sessions that examines both sides of various topics including stents, pharmacological strategy and thrombus aspiration. Attendees can expect vigorous debate, with convincing evidence on both sides.
It can sometimes be disorienting at such sessions where experts politely disagree. If experts can't see eye-to-eye on topics such as drug-eluting stents versus bare-metal stents for STEMI patients, then how can the local practice determine what's best for its patients? Sessions such as this one are a good way to hear the evidence and make an informed decision.
This symposium will cover a plethora of important topics such as whether to use glycoprotein IIb/IIIa inhibitors for all STEMI patients or if bivalirudin and thienopyridine are all that is needed. Another area where interventionalists often disagree is whether to routinely remove thrombus prior to PCI or not. A highlight of this session will be a debate on this topic, with one side arguing that the evidence for routine thrombectomy is lacking.
It might be that some practices can better incorporate one strategy over another. It might be that the prevalent patient population drives the therapeutic choice. Whatever the reasons, it's best to be informed and this session of experts arguing over best practices will be sure to enlighten.
Location: Room B313b
Dean J. Kereiakes, MD, Cincinnati
Roxana Mehran, MD, New York
Jose P. Henriques, MD, Amsterdam, Netherlands
Giuseppe De Luca, MD, Novara, Italy
David Faxon, MD, Boston
Christian Spaulding, MD, Paris
Bernard J. Gersh, MD, Rochester, Minn.